This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Quissak C, Litalien G, Alves MR.Cost-effectiveness analysis of dasatinib for the treatment of imatinib resistant or intolerant CML patients in Brazil. Value in Health 11: A64, No. 3, May-Jun 2008
Juarez-Garcia A, Zapata L, Vega G, Idrovo J, Rivas R, Kramis JL, Litalien G, Rangel S.The cost and cost effectiveness of dasatinib (Sprycel) therapy for the management of imatinib resistant and intolerant patients with chronic myeloid leukemia in Mexico. Value in Health 11: A157, No. 3, May-Jun 2008
Rights and permissions
About this article
Cite this article
Dasatinib fiestas while imatinib siestas in Latin America. Pharmacoecon. Outcomes News 555, 2 (2008). https://doi.org/10.2165/00151234-200805550-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805550-00001